{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:51:21Z","timestamp":1773924681746,"version":"3.50.1"},"reference-count":283,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C0360"],"award-info":[{"award-number":["HI22C0360"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.mam.2025.101441","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T22:30:07Z","timestamp":1765751407000},"page":"101441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical application"],"prefix":"10.1016","volume":"107","author":[{"given":"Ah Hyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9119-7317","authenticated-orcid":false,"given":"Sukmook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BST20241419","article-title":"Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro production","volume":"53","author":"Al-Seragi","year":"2025","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.mam.2025.101441_bib2","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2020.01986","article-title":"Phage display derived monoclonal antibodies: from bench to bedside","volume":"11","author":"Alfaleh","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/antib8030044","article-title":"Phage display libraries for antibody therapeutic discovery and development","volume":"8","author":"Almagro","year":"2019","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15537\/smj.2021.1.25663","article-title":"COVID-19 global health crisis","volume":"42","author":"Alokaily","year":"2021","journal-title":"Saudi Med. J."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.126","article-title":"SARS-CoV-2 Omicron variant: immune escape and vaccine development","volume":"3","author":"Ao","year":"2022","journal-title":"MedComm"},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib7","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.cell.2021.04.033","article-title":"Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia","volume":"184","author":"Asarnow","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141045","article-title":"A novel human scFv library with non-combinatorial synthetic CDR diversity","volume":"10","author":"Bai","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies"},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib12","doi-asserted-by":"crossref","first-page":"e00110","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-biodatasci-020722-041304","article-title":"Challenges and progress in designing broad-spectrum vaccines against rapidly mutating viruses","volume":"6","author":"Bedi","year":"2023","journal-title":"Annu. Rev. Biomed. Data Sci."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clinthera.2025.01.003","article-title":"Real-World effectiveness of sotrovimab in ambulatory patients with COVID-19: a retrospective cohort Study using a large administrative claims database in the United States","volume":"47","author":"Bell","year":"2025","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109433","article-title":"A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations","volume":"36","author":"Bertoglio","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41467-021-21609-2","article-title":"SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface","volume":"12","author":"Bertoglio","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2025.101441_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.630551","article-title":"Challenges associated with the Formation of recombinant protein inclusion bodies in Escherichia coli and strategies to address them for industrial applications","volume":"9","author":"Bhatwa","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mam.2025.101441_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-4939-2748-7_3","article-title":"Combining phage and yeast cell surface antibody display to identify novel cell type-selective internalizing human monoclonal antibodies","volume":"1319","author":"Bidlingmaier","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib19","series-title":"Medical Biochemistry","first-page":"811","article-title":"Molecular basis of immunity","author":"Blanco","year":"2022"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","article-title":"Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2","volume":"17","author":"Bracken","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2004.04.007","article-title":"Antibodies from phage antibody libraries","volume":"290","author":"Bradbury","year":"2004","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2337312","article-title":"New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation","volume":"16","author":"Bratkovi\u010d","year":"2024","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"697","key":"10.1016\/j.mam.2025.101441_bib24","doi-asserted-by":"crossref","first-page":"eadf4549","DOI":"10.1126\/scitranslmed.adf4549","article-title":"A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo","volume":"15","author":"Burn Aschner","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19780-7","article-title":"Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies","volume":"12","author":"Cao","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2025.101441_bib26","article-title":"Discovery and development of human SARS-CoV-2 neutralizing antibodies using an unbiased phage display Library approach","author":"Cao","year":"2020","journal-title":"bioRxiv preprint"},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib27","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.immuni.2024.06.013","article-title":"Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex","volume":"57","author":"Carr","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.mam.2025.101441_bib28","series-title":"Proof and Concepts in Rapid Diagnostic Tests and Technologies","first-page":"107","article-title":"Phage display\u2010derived antibodies: application of recombinant antibodies for diagnostics","author":"Ch\u2019ng","year":"2016"},{"key":"10.1016\/j.mam.2025.101441_bib29","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.2147\/IJGM.S419789","article-title":"Re-Emerging COVID-19: controversy of its zoonotic origin, risks of severity of reinfection and management","volume":"16","author":"Chala","year":"2023","journal-title":"Int. J. Gen. Med."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/intimm\/dxu082","article-title":"The role of phage display in therapeutic antibody discovery","volume":"26","author":"Chan","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.mam.2025.101441_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-319-72077-7_3","article-title":"Na\u00efve human antibody libraries for infectious diseases","volume":"1053","author":"Chan","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib32","article-title":"Potent neutralization of Omicron and other SARS-CoV-2 variants of concern by Biparatopic Human VH domains","author":"Chen","year":"2022","journal-title":"bioRxiv preprint"},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156798","article-title":"Discovery and characterization of phage display-derived human monoclonal antibodies against RSV F glycoprotein","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2025.101441_bib35","article-title":"Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants","author":"Chen","year":"2022","journal-title":"medRxiv preprint"},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib36","article-title":"An engineered IgG-VHH bispecific antibody against SARS-CoV-2 and its variants","volume":"6","author":"Chi","year":"2022","journal-title":"Small Methods"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib37","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1038\/s41467-020-18387-8","article-title":"Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain","volume":"11","author":"Chi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-022-00912-4","article-title":"An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants","volume":"7","author":"Chi","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2025.101441_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.803041","article-title":"A novel toll-like receptor 2 agonist protects mice in a prophylactic treatment model against challenge with Bacillus anthracis","volume":"13","author":"Chiang","year":"2022","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.18699\/VJ21.063","article-title":"Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies","volume":"25","author":"Chikaev","year":"2021","journal-title":"Vavilov J. Genet. Breed."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib42","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.3390\/ijms24066011","article-title":"Generation and next-generation sequencing-based characterization of a large human combinatorial antibody Library","volume":"24","author":"Choi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/19420862.2015.1076600","article-title":"Antibody humanization by structure-based computational protein design","volume":"7","author":"Choi","year":"2015","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01587-23","article-title":"Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab\/cilgavimab) in the prophylaxis and treatment of COVID-19","volume":"68","author":"Clegg","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.mam.2025.101441_bib45","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell"},{"issue":"6279","key":"10.1016\/j.mam.2025.101441_bib46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tibtech.2010.03.007","article-title":"Multivalent antibodies: when design surpasses evolution","volume":"28","author":"Cuesta","year":"2010","journal-title":"Trends Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib48","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1038\/s41467-020-19204-y","article-title":"Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2","volume":"11","author":"Cust\u00f3dio","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.mam.2025.101441_bib51","article-title":"Safety, tolerability and pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 monoclonal antibody","year":"2020","journal-title":"Healthy Chinese Subjects"},{"issue":"33","key":"10.1016\/j.mam.2025.101441_bib65","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antib12010007","article-title":"Therapeutic phage display-derived single-domain antibodies for pandemic preparedness","volume":"12","author":"Daly","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.mam.2025.101441_bib67","first-page":"1","article-title":"The landscape of neutralizing monoclonal antibodies (nAbs) for treatment and prevention of COVID-19","author":"de Almeida Oliveira","year":"2023","journal-title":"J. Pharm. Innov."},{"issue":"26","key":"10.1016\/j.mam.2025.101441_bib68","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1074\/jbc.274.26.18218","article-title":"A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies","volume":"274","author":"de Haard","year":"1999","journal-title":"Biol. Chem."},{"key":"10.1016\/j.mam.2025.101441_bib69","author":"Deb"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-025-00764-4","article-title":"Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools","volume":"13","author":"Dewaker","year":"2025","journal-title":"Biomarker Res"},{"key":"10.1016\/j.mam.2025.101441_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2025.101496","article-title":"Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: a Phase II clinical trial","volume":"45","author":"Diaz","year":"2025","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.mam.2025.101441_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.965446","article-title":"Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library","volume":"13","author":"Dormeshkin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mam.2025.101441_bib74","article-title":"Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19","author":"Dougan","year":"2022","journal-title":"medRxiv preprint"},{"issue":"1 Suppl. 1","key":"10.1016\/j.mam.2025.101441_bib75","article-title":"Control and prevention of infectious diseases from a one Health perspective","volume":"44","author":"Ellwanger","year":"2021","journal-title":"Genet. Mol. Biol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib77","first-page":"112","article-title":"Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review","volume":"5","author":"Farooqi","year":"2020","journal-title":"Trop. Med. Infect. Dis."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib79","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jmb.2007.08.005","article-title":"High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries","volume":"373","author":"Fellouse","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"34","key":"10.1016\/j.mam.2025.101441_bib80","doi-asserted-by":"crossref","first-page":"12467","DOI":"10.1073\/pnas.0401786101","article-title":"Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition","volume":"101","author":"Fellouse","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib81","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41467-021-27799-z","article-title":"A pandemic-enabled comparison of discovery platforms demonstrates a na\u00efve antibody library can match the best immune-sourced antibodies","volume":"13","author":"Ferrara","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049535","article-title":"Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker","volume":"7","author":"Ferrara","year":"2012","journal-title":"PLoS One"},{"issue":"1904","key":"10.1016\/j.mam.2025.101441_bib83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-4939-8958-4_16","article-title":"Recombinant antibody selections by combining phage and yeast display","author":"Ferrara","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib84","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/v14091999","article-title":"A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld\u2122) for COVID-19 prophylaxis and treatment","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.mam.2025.101441_bib85","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cmi.2024.04.012","article-title":"An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2","volume":"30","author":"Focosi","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"issue":"14","key":"10.1016\/j.mam.2025.101441_bib86","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.3390\/ijms23147805","article-title":"New anti-flavivirus fusion loop human antibodies with zika virus-neutralizing potential","volume":"23","author":"Fran\u00e7a","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib87","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"mAbs"},{"issue":"19","key":"10.1016\/j.mam.2025.101441_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151697","article-title":"Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19","volume":"131","author":"Ganesh","year":"2021","journal-title":"Clin. Invest."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101622","article-title":"Phage-DMS: a comprehensive method for fine mapping of antibody epitopes","volume":"23","author":"Garrett","year":"2020","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13036-024-00418-3","article-title":"Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation","volume":"18","author":"Go","year":"2024","journal-title":"J. Biol. Eng."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/antib11030057","article-title":"In vitro and in vivo characterization of a broadly neutralizing Anti-SARS-CoV-2 antibody isolated from a semi-immune phage display Library","volume":"11","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.mam.2025.101441_bib93","first-page":"597","article-title":"Immunizing schedules for hybridoma production","volume":"5","author":"Gustafsson","year":"1990","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biologicals.2013.04.001","article-title":"Phage display antibodies for diagnostic applications","volume":"41","author":"Hairul Bahara","year":"2013","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2013.521","article-title":"Antibody phage display: technique and applications","volume":"134","author":"Hammers","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib96","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1779974","article-title":"Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 Hinge region","volume":"12","author":"Handlogten","year":"2020","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tips.2021.11.010","article-title":"Deep mutational scanning for therapeutic antibody engineering","volume":"43","author":"Hanning","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib98","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/microorganisms11020445","article-title":"Evaluating the virology and evolution of seasonal human coronaviruses associated with the common cold in the COVID-19 era","volume":"11","author":"Harrison","year":"2023","journal-title":"Microorganisms"},{"issue":"8","key":"10.1016\/j.mam.2025.101441_bib99","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/acs.molpharmaceut.4c00165","article-title":"Development of broad-spectrum nanobodies for the therapy and diagnosis of SARS-CoV-2 and its multiple variants","volume":"21","author":"He","year":"2024","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib100","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41564-022-01235-4","article-title":"SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope","volume":"7","author":"He","year":"2022","journal-title":"Nat. Microbiol."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.nano.2016.08.006","article-title":"RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine","volume":"13","author":"Herv\u00e9","year":"2017","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib102","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nbt1067","article-title":"Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity","volume":"23","author":"Hoet","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib103","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mam.2025.101441_bib104","article-title":"Generation of Murine monoclonal antibodies by hybridoma technology","volume":"119","author":"Holzl\u00f6hner","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib108","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1021\/acsinfecdis.5c00205","article-title":"A high-affinity and potently neutralized nanobody against zika virus","volume":"11","author":"Hu","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.mam.2025.101441_bib109","article-title":"Highly reliable GIGA-sized synthetic human therapeutic antibody library construction","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib110","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/nprot.2013.117","article-title":"Isolation of human monoclonal antibodies from peripheral blood B cells","volume":"8","author":"Huang","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mam.2025.101441_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1097661","article-title":"Editorial: phage display: technique and applications","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib112","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mam.2025.101441_bib114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nbt.2024.08.506","article-title":"Phage display for discovery of anticancer antibodies","volume":"83","author":"Istomina","year":"2024","journal-title":"N. Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib116","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0958-1669(95)80093-X","article-title":"Production of fully human antibodies by transgenic mice","volume":"6","author":"Jakobovits","year":"1995","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.mam.2025.101441_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.612541","article-title":"Barriers influencing vaccine development timelines, identification, causal analysis, and prioritization of key barriers by KOLs in general and Covid-19 vaccine R&D","volume":"9","author":"Janse","year":"2021","journal-title":"Front. Public Health"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib119","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41401-021-00707-3","article-title":"A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms","volume":"43","author":"Jin","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"593","key":"10.1016\/j.mam.2025.101441_bib120","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mam.2025.101441_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101964","article-title":"Individual-and population-associated heterogeneity in vaccine-induced immune responses. The impact of inflammatory status and diabetic comorbidity","volume":"78","author":"Joosten","year":"2025","journal-title":"Semin. Immunol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib122","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jac\/dkad076","article-title":"Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants","volume":"78","author":"Jorgensen","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib123","doi-asserted-by":"crossref","first-page":"bbae307","DOI":"10.1093\/bib\/bbae307","article-title":"Antibody design using deep learning: from sequence and structure design to affinity maturation","volume":"25","author":"Joubbi","year":"2024","journal-title":"Briefings Bioinf."},{"issue":"7838","key":"10.1016\/j.mam.2025.101441_bib124","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib125","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40265-022-01731-1","article-title":"Tixagevimab + Cilgavimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib126","first-page":"37","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2023","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib127","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/v15010174","article-title":"Development and characterization of phage display-derived monoclonal antibodies to the S2 domain of spike proteins of wild-type SARS-CoV-2 and multiple variants","volume":"15","author":"Kim","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.mam.2025.101441_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105576","article-title":"Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants","volume":"212","author":"Kim","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mam.2025.101441_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1271508","article-title":"A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants","volume":"14","author":"Kim","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29506","article-title":"Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides","volume":"96","author":"Kim","year":"2024","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib132","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.3390\/biomedicines10123274","article-title":"Development and characterization of phage-display-derived novel human monoclonal antibodies against the receptor binding domain of SARS-CoV-2","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.mam.2025.101441_bib133","article-title":"Nanobodies: robust miniprotein binders in biomedicine","volume":"195","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib134","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jim.2007.10.009","article-title":"Selection of an affinity-matured antibody against a defined epitope by phage display of an immune antibody library","volume":"329","author":"Kim","year":"2008","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1016-8478(23)25245-0","article-title":"Antibody engineering for the development of therapeutic antibodies","volume":"20","author":"Kim","year":"2005","journal-title":"Mol. Cells"},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib136","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib137","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/jmbi.1999.3444","article-title":"Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides","volume":"296","author":"Knappik","year":"2000","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib138","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12985-023-02230-9","article-title":"Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants","volume":"20","author":"Ko","year":"2023","journal-title":"Virol. J."},{"issue":"17","key":"10.1016\/j.mam.2025.101441_bib139","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/cbic.201200493","article-title":"Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein","volume":"13","author":"Koellhoffer","year":"2012","journal-title":"Chembiochem"},{"issue":"6530","key":"10.1016\/j.mam.2025.101441_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"issue":"7869","key":"10.1016\/j.mam.2025.101441_bib141","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","article-title":"Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants","volume":"595","author":"Ku","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib142","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1038\/s41467-022-33284-y","article-title":"Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth","volume":"13","author":"Ku","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib143","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/phar.1990","article-title":"Bezlotoxumab: a novel agent for the prevention of recurrent Clostridium difficile infection","volume":"37","author":"Kufel","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mam.2025.101441_bib144","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","article-title":"Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies","volume":"135","author":"Kumar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib145","doi-asserted-by":"crossref","DOI":"10.1063\/5.0158032","article-title":"Protein engineering of antibody fragments for pharmaceutical production","volume":"10","author":"Kuwahara","year":"2023","journal-title":"Appl. Phys. Rev."},{"issue":"13","key":"10.1016\/j.mam.2025.101441_bib146","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mam.2025.101441_bib147","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijbiomac.2020.06.268","article-title":"Infectious disease antibodies for biomedical applications: a mini review of immune antibody phage library repertoire","volume":"163","author":"Lai","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib148","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.tibtech.2021.03.003","article-title":"Animal immunization, in vitro display technologies, and machine learning for antibody discovery","volume":"39","author":"Laustsen","year":"2021","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.mam.2025.101441_bib149","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.drudis.2022.05.002","article-title":"Advances in antibody phage display technology","volume":"27","author":"Ledsgaard","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib150","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.3390\/ijms25094791","article-title":"Development, high-throughput profiling, and biopanning of a large phage display single-domain antibody Library","volume":"25","author":"Lee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib151","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jmb.2004.05.051","article-title":"High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold","volume":"340","author":"Lee","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib152","article-title":"Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform","volume":"48","author":"Li","year":"2025","journal-title":"Biotechnol. Rep."},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib153","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib154","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13578-022-00794-7","article-title":"Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib155","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1038\/s41467-023-39022-2","article-title":"Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2025.101441_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.342978","article-title":"Microfluidics, an effective tool for supporting phage display-A review","volume":"1326","author":"Li","year":"2024","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.mam.2025.101441_bib157","article-title":"A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection","author":"Li","year":"2020","journal-title":"bioRxiv preprint"},{"issue":"47","key":"10.1016\/j.mam.2025.101441_bib158","doi-asserted-by":"crossref","first-page":"29832","DOI":"10.1073\/pnas.2010197117","article-title":"Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3515","article-title":"General strategies for IgG-like bispecific antibody purification","volume":"41","author":"Li","year":"2025","journal-title":"Biotechnol. Prog."},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib160","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01063-21","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: a randomized, Double-Blind, Placebo-Controlled, phase I Study","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mam.2025.101441_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1100263","article-title":"SARS-CoV-2 neutralizing antibody bebtelovimab \u2013 a systematic scoping review and meta-analysis","volume":"14","author":"Liew","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib162","first-page":"37","article-title":"Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients","volume":"11","author":"Lim","year":"2023","journal-title":"J. Intensive Care"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib163","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1893426","article-title":"Bispecific VH\/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2","volume":"13","author":"Lim","year":"2021","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib164","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41598-020-58571-w","article-title":"A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line","volume":"10","author":"Listek","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2025.101441_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105941","article-title":"Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life","volume":"165","author":"Liu","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib166","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions\u2014improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"issue":"43","key":"10.1016\/j.mam.2025.101441_bib167","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi4582","article-title":"Structural basis for selective modification of Rho and Ras GTPases by Clostridioides difficile toxin B","volume":"7","author":"Liu","year":"2021","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib168","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/protein\/gzn058","article-title":"Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens","volume":"22","author":"Lloyd","year":"2009","journal-title":"Protein Eng. Des. Sel."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib169","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/jpc.16643","article-title":"Nirsevimab: alleviating the burden of RSV morbidity in young children","volume":"60","author":"Loe","year":"2024","journal-title":"J. Paediatr. Child Health"},{"issue":"23","key":"10.1016\/j.mam.2025.101441_bib170","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1074\/jbc.RA118.002538","article-title":"Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging","volume":"293","author":"Long","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib171","first-page":"307","article-title":"AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains","volume":"7","author":"Loomis","year":"2024","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib173","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41421-022-00497-w","article-title":"A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91596-3","article-title":"Anthrax toxin translocation complex reveals insight into the lethal factor unfolding and refolding mechanism","volume":"11","author":"Machen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2025.101441_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib176","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14712598.2024.2336068","article-title":"IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents","volume":"24","author":"Madsen","year":"2024","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.mam.2025.101441_bib177","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijbiomac.2022.03.113","article-title":"An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages","volume":"208","author":"Mahdavi","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib178","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","article-title":"Complement component 5a (c5a)","volume":"41","author":"Manthey","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib179","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12929-025-01141-x","article-title":"Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning","volume":"32","author":"Matsunaga","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib181","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib182","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/viro.1997.8547","article-title":"A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event","volume":"233","author":"McInerney","year":"1997","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib184","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antib11010013","article-title":"Anti-SARS-CoV-2 Omicron antibodies isolated from a SARS-CoV-2 Delta semi-immune phage display Library","volume":"11","author":"Mendoza-Salazar","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.mam.2025.101441_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1207313","article-title":"Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations","volume":"13","author":"Meredith","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"19","key":"10.1016\/j.mam.2025.101441_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167177","article-title":"Tetravalent SARS-CoV-2 neutralizing antibodies show enhanced potency and resistance to escape mutations","volume":"433","author":"Miersch","year":"2021","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110905","article-title":"Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies","volume":"39","author":"Miersch","year":"2022","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib188","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2025.101441_bib189","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib190","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ymthe.2022.02.013","article-title":"Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy","volume":"30","author":"Minenkova","year":"2022","journal-title":"Mol. Ther."},{"issue":"768","key":"10.1016\/j.mam.2025.101441_bib191","doi-asserted-by":"crossref","first-page":"eado9026","DOI":"10.1126\/scitranslmed.ado9026","article-title":"A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo","volume":"16","author":"Misasi","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib192","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43141-021-00264-6","article-title":"Hybridoma technology; advancements, clinical significance, and future aspects","volume":"19","author":"Mitra","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib193","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1073\/pnas.102562599","article-title":"Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes","volume":"99","author":"Moulard","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2024.01.001","article-title":"Developing recombinant antibodies by phage display technology to neutralize viral infectious diseases","volume":"29","author":"Mustafa","year":"2024","journal-title":"SLAS Discov."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229027","article-title":"R409K mutation prevents acid-induced aggregation of human IgG4","volume":"15","author":"Namisaki","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2025.101441_bib196","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-61779-921-1_2","article-title":"Synthetic antibody libraries","volume":"899","author":"Nelson","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib197","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4161\/mabs.27240","article-title":"Drugs derived from phage display: from candidate identification to clinical practice","volume":"6","author":"Nixon","year":"2014","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib198","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0022-1759(84)90233-3","article-title":"An ELISA for screening hybridoma cultures for monoclonal antibodies against a detergent solubilized integral membrane protein","volume":"75","author":"Noteboom","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib199","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1038\/s41467-020-18159-4","article-title":"A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes","volume":"11","author":"Noy-Porat","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102479","article-title":"Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice","volume":"24","author":"Noy-Porat","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib201","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40200-024-01386-7","article-title":"A mini review on recent progress of microfluidic systems for antibody development","volume":"23","author":"Omidfar","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41421-021-00295-w","article-title":"Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries","volume":"7","author":"Pan","year":"2021","journal-title":"Cell Discov."},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib203","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib204","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.biologicals.2003.08.003","article-title":"Stability of murine, chimeric and humanized antibodies against pre-S2 surface antigen of hepatitis B virus","volume":"31","author":"Park","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.mam.2025.101441_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106639","article-title":"Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives","volume":"85","author":"Parray","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib206","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1128\/JVI.72.5.3512-3519.1998","article-title":"Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity","volume":"72","author":"Parren","year":"1998","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib207","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/19420862.2019.1618673","article-title":"A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing","volume":"11","author":"Parthiban","year":"2019","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib208","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s40121-024-01031-z","article-title":"Efficacy and safety of Low-Dose, rapidly infused bamlanivimab and etesevimab: phase 3 BLAZE-1 trial for mild-to-moderate COVID-19","volume":"13","author":"Patel","year":"2024","journal-title":"Infect. Dis. Ther."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib209","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.it.2021.10.008","article-title":"Single B cell technologies for monoclonal antibody discovery","volume":"42","author":"Pedrioli","year":"2021","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib210","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib211","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acscentsci.1c01205","article-title":"Rapid on-cell selection of high-performance human antibodies","volume":"8","author":"Philpott","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"7815","key":"10.1016\/j.mam.2025.101441_bib212","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib213","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/bioengineering10020122","article-title":"Bioengineering of antibody fragments: challenges and opportunities","volume":"10","author":"Pirkalkhoran","year":"2023","journal-title":"Bioengineering"},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136778","article-title":"A Robust and Versatile method of combinatorial chemical synthesis of gene libraries via hierarchical assembly of partially randomized modules","volume":"10","author":"Popova","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib216","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/pharmaceutics12100937","article-title":"Brain delivery of single-domain antibodies: a focus on VHH and VNAR","volume":"12","author":"Pothin","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib217","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmb.2011.08.012","article-title":"HuCAL PLATINUM, a synthetic Fab Library optimized for sequence diversity and Superior performance in Mammalian expression systems","volume":"413","author":"Prassler","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"S11","key":"10.1016\/j.mam.2025.101441_bib218","first-page":"355","article-title":"Biologics vs. small molecule drugs: comparing efficacy and safety","volume":"7","author":"Quraee","year":"2024","journal-title":"J. Int. Crisis Risk Commun. Res."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib219","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/s41467-023-37826-w","article-title":"Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy","volume":"14","author":"Ragonnet-Cronin","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib220","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/vaccines9101195","article-title":"Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy","volume":"9","author":"Ramesh","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib221","first-page":"260","article-title":"Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell host","volume":"31","author":"Rayaprolu","year":"2023","journal-title":"Microbe"},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib222","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12033-019-00207-0","article-title":"Advances in the production and batch reformatting of phage antibody libraries","volume":"61","author":"Reader","year":"2019","journal-title":"Mol. Biotechnol."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib223","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012328","article-title":"Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis","volume":"8","author":"Relan","year":"2023","journal-title":"BMJ Glob. Health"},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib224","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/hyb.2004.23.373","article-title":"Development of a quantitative cell-based intracellular ELISA for the screening of B cell hybridoma supernatants: a novel rapid assay to detect positive clones","volume":"23","author":"Renukaradhya","year":"2004","journal-title":"Hybrid. Hybridomics"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib225","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61230-z","article-title":"Development of a new affinity maturation protocol for the construction of an internalizing anti-nucleolin antibody library","volume":"14","author":"Ribeiro","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11274-024-03990-4","article-title":"Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons","volume":"40","author":"Rizk","year":"2024","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.mam.2025.101441_bib227","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.697876","article-title":"Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy","volume":"11","author":"Roth","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib228","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jmb.2007.12.018","article-title":"The human combinatorial antibody Library HuCAL GOLD combines diversification of all six CDRs according to the natural immune System with a novel display method for efficient selection of high-affinity antibodies","volume":"376","author":"Rothe","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib229","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fimmu.2018.00118","article-title":"Next-generation sequencing of antibody display repertoires","volume":"9","author":"Rouet","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib230","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1038\/s41467-021-23825-2","article-title":"Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers","volume":"12","author":"Rujas","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib231","first-page":"141","article-title":"Hybridoma technology for the production of monoclonal antibodies","volume":"8","author":"Sait","year":"2022","journal-title":"D. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib232","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0891-5245(99)90039-1","article-title":"Palivizumab for respiratory syncytial virus prophylaxis","volume":"13","author":"Sandritter","year":"1999","journal-title":"J. Paediatr. Health Care"},{"issue":"9\u201310","key":"10.1016\/j.mam.2025.101441_bib233","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/elps.202200187","article-title":"Selection of phage-displayed antibodies with high affinity and specificity by electrophoresis in microfluidic devices","volume":"44","author":"Sanluis-Verdes","year":"2023","journal-title":"Electrophoresis"},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib234","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/651603","article-title":"Pharmacologic advances in the treatment and prevention of respiratory syncytial virus","volume":"50","author":"Saravolatz","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.140321","article-title":"Unbiased libraries in protein directed evolution","volume":"1868","author":"Sayous","year":"2020","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"27","key":"10.1016\/j.mam.2025.101441_bib236","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib237","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40259-024-00667-0","article-title":"Monoclonal antibody generation using single B cell screening for treating infectious diseases","volume":"38","author":"Schardt","year":"2024","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib238","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/BF02618605","article-title":"Present status and future prospects for the hybridoma technology","volume":"17","author":"Scharff","year":"1981","journal-title":"In Vitro"},{"issue":"621","key":"10.1016\/j.mam.2025.101441_bib239","doi-asserted-by":"crossref","first-page":"eabi7826","DOI":"10.1126\/scitranslmed.abi7826","article-title":"An affinity-enhanced, broadly neutralizing heavy chain\u2013only antibody protects against SARS-CoV-2 infection in animal models","volume":"13","author":"Schepens","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"19","key":"10.1016\/j.mam.2025.101441_bib240","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMc2404555","article-title":"Immunobridging for pemivibart, a monoclonal antibody for prevention of Covid-19","volume":"391","author":"Schmidt","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.mam.2025.101441_bib241","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jim.2013.02.010","article-title":"Discovery of diverse and functional antibodies from large human repertoire antibody libraries","volume":"391","author":"Schwimmer","year":"2013","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib242","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1080\/22221751.2022.2117094","article-title":"Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"11","author":"Seo","year":"2022","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.mam.2025.101441_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105442","article-title":"Clinical and experimental bacteriophage studies: recommendations for possible approaches for standing against SARS-CoV-2","volume":"164","author":"Shahin","year":"2022","journal-title":"Microb. Pathog."},{"issue":"6704","key":"10.1016\/j.mam.2025.101441_bib244","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1126\/science.adk8946","article-title":"Unsupervised evolution of protein and antibody complexes with a structure-informed language model","volume":"385","author":"Shanker","year":"2024","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.mam.2025.101441_bib245","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.3390\/molecules28186438","article-title":"Therapeutic antibodies in medicine","volume":"28","author":"Sharma","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib246","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med."},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib247","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio843","article-title":"Synthetic therapeutic antibodies","volume":"2","author":"Sidhu","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.mam.2025.101441_bib248","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmb.2004.02.050","article-title":"Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions","volume":"338","author":"Sidhu","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib249","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2553622","article-title":"Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study","volume":"17","author":"Siegmund","year":"2025","journal-title":"mAbs"},{"issue":"12","key":"10.1016\/j.mam.2025.101441_bib250","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4049\/immunohorizons.2300102","article-title":"Recent advances in the development of monoclonal antibodies and next-generation antibodies","volume":"7","author":"Singh","year":"2023","journal-title":"Immunohorizons"},{"issue":"40","key":"10.1016\/j.mam.2025.101441_bib251","doi-asserted-by":"crossref","first-page":"16095","DOI":"10.1073\/pnas.1208857109","article-title":"Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions","volume":"109","author":"Sockolosky","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.mam.2025.101441_bib252","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib253","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nbt.2677","article-title":"Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1\u2013neutralizing activity","volume":"31","author":"Song","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12896-019-0577-8","article-title":"The next generation of biopanning: next gen sequencing improves analysis of bacterial display libraries","volume":"19","author":"Stellwagen","year":"2019","journal-title":"BMC Biotechnol."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib256","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/psp4.70048","article-title":"Target-Mediated drug disposition (TMDD) revisited: high versus low-affinity approximations of the TMDD model","volume":"14","author":"Straube","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib257","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1778435","article-title":"Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold","volume":"12","author":"Sun","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.mam.2025.101441_bib258","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1083429","article-title":"Ebanga\u2122: the most recent FDA-approved drug for treating Ebola","volume":"14","author":"Taki","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib259","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/s41467-022-30698-6","article-title":"Transmission of SARS-CoV-2 from humans to animals and potential host adaptation","volume":"13","author":"Tan","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib260","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47086-9","article-title":"Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate","volume":"13","author":"Tanelus","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.mam.2025.101441_bib261","first-page":"303","article-title":"Respiratory syncytial virus-associated respiratory diseases in children and adults","volume":"121","author":"Tenenbaum","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib263","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/mabs.24218","article-title":"A fully synthetic human Fab antibody library based on fixed VH\/VL framework pairings with favorable biophysical properties","volume":"5","author":"Tiller","year":"2013","journal-title":"mAbs"},{"issue":"Pt 6","key":"10.1016\/j.mam.2025.101441_bib264","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/icb.1990.50","article-title":"Development of human anti-murine antibody (HAMA) response in patients","volume":"68","author":"Tjandra","year":"1990","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib265","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt.11.4","article-title":"Hybridoma technologies for antibody production","volume":"3","author":"Tomita","year":"2011","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib266","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41525-3","article-title":"Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli","volume":"13","author":"Tungekar","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2025.101441_bib267","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-72077-7_6","article-title":"Monoclonal antibodies and antibody like fragments derived from immunised phage display libraries","volume":"1053","author":"Ubah","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib268","article-title":"UniProtKB entry P0DTC2 (SPIKE_SARS2)","year":"2025","journal-title":"UniProt, release 2025_03"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib269","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"mAbs"},{"issue":"1951","key":"10.1016\/j.mam.2025.101441_bib270","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody Formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib271","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display Library","volume":"14","author":"Vaughan","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib272","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2528902","article-title":"Artificial intelligence-driven computational methods for antibody design and optimization","volume":"17","author":"Vecchietti","year":"2025","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib273","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/cts.13213","article-title":"The anti\u2010C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID\u201019","volume":"15","author":"Vlaar","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/j.mam.2025.101441_bib274","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/19420862.2018.1511198","article-title":"A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture","volume":"10","author":"Wang","year":"2018","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.mam.2025.101441_bib275","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1039\/D0LC01146K","article-title":"Highly paralleled emulsion droplets for efficient isolation, amplification, and screening of cancer biomarker binding phages","volume":"21","author":"Wang","year":"2021","journal-title":"Lab Chip"},{"issue":"19","key":"10.1016\/j.mam.2025.101441_bib276","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMc2410203","article-title":"Activity of research-grade pemivibart against recent SARS-CoV-2 JN. 1 sublineages","volume":"391","author":"Wang","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib277","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13036-025-00513-z","article-title":"High-throughput strategies for monoclonal antibody screening: advances and challenges","volume":"19","author":"Wang","year":"2025","journal-title":"J. Biol. Eng."},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib278","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.chest.2023.06.004","article-title":"Effectiveness of bebtelovimab against hospitalization and death from the Omicron BA.4\/BA.5 and BQ.1\/BQ.1.1 subvariants","volume":"164","author":"Wang","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.mam.2025.101441_bib279","article-title":"Comparison of \"framework Shuffling\" and \"CDR Grafting\" in humanization of a PD-1 murine antibody","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.mam.2025.101441_bib280","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3839","article-title":"High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib281","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41421-022-00509-9","article-title":"Biparatopic antibody BA7208\/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Discov."},{"issue":"W1","key":"10.1016\/j.mam.2025.101441_bib282","doi-asserted-by":"crossref","first-page":"W639","DOI":"10.1093\/nar\/gkac508","article-title":"REVERSE: a user-friendly web server for analyzing next-generation sequencing data from in vitro selection\/evolution experiments","volume":"50","author":"Weiss","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.mam.2025.101441_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib286","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4161\/mabs.23941","article-title":"Monovalent IgG4 molecules: Immunoglobulin Fc mutations that result in a monomeric structure","volume":"5","author":"Wilkinson","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.mam.2025.101441_bib287","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.2147\/IJN.S427990","article-title":"A naive phage display library-derived nanobody neutralizes SARS-CoV-2 and three variants of concern","volume":"18","author":"Wu","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib288","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib289","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.gpb.2023.03.004","article-title":"AB-Gen: Antibody Library design with generative pre-trained transformer and deep reinforcement learning","volume":"21","author":"Xu","year":"2023","journal-title":"Genom. Proteom. Bioinform."},{"issue":"18","key":"10.1016\/j.mam.2025.101441_bib290","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00485-21","article-title":"Potent human single-domain antibodies specific for a novel prefusion epitope of respiratory syncytial virus F glycoprotein","volume":"95","author":"Xun","year":"2021","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.mam.2025.101441_bib291","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1128\/AAC.01102-16","article-title":"Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mam.2025.101441_bib292","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","article-title":"Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-Based therapeutics","volume":"8","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib293","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.22","article-title":"Next-generation sequencing enables the discovery of more diverse positive clones from a phage-displayed antibody library","volume":"49","author":"Yang","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.mam.2025.101441_bib294","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular Architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41422-020-00444-y","article-title":"Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection","volume":"31","author":"Yao","year":"2021","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.mam.2025.101441_bib296","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01448-23","article-title":"Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19","volume":"97","author":"Ye","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.mam.2025.101441_bib297","article-title":"A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron","author":"Yuan","year":"2022","journal-title":"bioRxiv preprint"},{"issue":"4","key":"10.1016\/j.mam.2025.101441_bib298","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/v15040944","article-title":"Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies","volume":"15","author":"Zabidi","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib299","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jmb.2011.07.018","article-title":"Synthetic antibodies designed on natural sequence landscapes","volume":"412","author":"Zhai","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib300","article-title":"An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variants","author":"Zhang","year":"2021","journal-title":"bioRxiv preprint"},{"issue":"8","key":"10.1016\/j.mam.2025.101441_bib301","doi-asserted-by":"crossref","first-page":"nwab053","DOI":"10.1093\/nsr\/nwab053","article-title":"A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2","volume":"8","author":"Zhang","year":"2021","journal-title":"Natl. Sci. Rev."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib302","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1904546","article-title":"A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies","volume":"13","author":"Zhang","year":"2021","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib303","doi-asserted-by":"crossref","first-page":"22","DOI":"10.52601\/bpr.2023.230026","article-title":"Generation and characterization of nanobodies targeting GPCR","volume":"10","author":"Zhang","year":"2024","journal-title":"Biophys. Rep."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib304","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2213793","article-title":"Evolution of phage display libraries for therapeutic antibody discovery","volume":"15","author":"Zhang","year":"2023","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib305","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12951-022-01619-y","article-title":"A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode","volume":"20","author":"Zhao","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101441_bib306","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms12010001","article-title":"Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity","volume":"12","author":"Zhao","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2025.101441_bib308","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-1-61779-974-7_17","article-title":"Mammalian cell surface display of full length IgG","volume":"907","author":"Zhou","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mam.2025.101441_bib309","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114242","article-title":"SARS-CoV-2 E protein: pathogenesis and potential therapeutic development","volume":"159","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.mam.2025.101441_bib310","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: From discovery to AI-driven design","volume":"14","author":"Zhu","year":"2025","journal-title":"Biology"}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299725001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299725001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:01:50Z","timestamp":1773910910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299725001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":283,"alternative-id":["S0098299725001050"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2025.101441","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical application","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2025.101441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101441"}}